Sheryl A Kingsberg1, Stanley Althof2, James A Simon3, Andrea Bradford4, Johannes Bitzer5, Joana Carvalho6, Kathryn E Flynn7, Rossella E Nappi8, Jennifer B Reese9, Roya L Rezaee1, Leslie Schover10, Jan L Shifrin11. 1. Case Western Reserve University Medical School, Cleveland, OH, USA. 2. Case Western Reserve University Medical School, Cleveland, OH, USA. Electronic address: stanley.althof@case.edu. 3. George Washington University School of Medicine, Washington, DC, USA. 4. Baylor College of Medicine, Houston, TX, USA. 5. University Hospital, Basel, Switzerland. 6. Lusófona University, Lisbon, Portugal. 7. Medical College of Wisconsin, Milwaukee, WI, USA. 8. University of Pavia, Pavia, Italy. 9. Fox Chase Cancer Center, Philadelphia, PA, USA. 10. Will2Love, Houston, TX, USA. 11. Massachusetts General Hospital, Boston, MA, USA.
Abstract
INTRODUCTION: Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner. AIMS: To review the literature and describe the best practices for assessing and treating women with hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. METHODS: The committee undertook a comprehensive review of the literature and discussion among themselves to determine the best assessment and treatment methods. RESULTS: Using a biopsychosocial lens, the committee presents recommendations (with levels of evidence) for assessment and treatment of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. CONCLUSION: The numerous significant strides in FSD that have occurred since the previous International Consultation of Sexual Medicine publications are reviewed in this article. Although evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, the biological and psychological factors are artificially separated for review purposes. We recognize that best outcomes are achieved when all relevant factors are identified and addressed by the clinician and patient working together in concert (the sum is greater than the whole of its parts). Kingsberg SA, Althof S, Simon JA, et al. Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14. J Sex Med 2017;14:1463-1491.
INTRODUCTION: Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner. AIMS: To review the literature and describe the best practices for assessing and treating women with hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. METHODS: The committee undertook a comprehensive review of the literature and discussion among themselves to determine the best assessment and treatment methods. RESULTS: Using a biopsychosocial lens, the committee presents recommendations (with levels of evidence) for assessment and treatment of hypoactive sexual desire disorder, female sexual arousal disorder, and female orgasmic disorders. CONCLUSION: The numerous significant strides in FSD that have occurred since the previous International Consultation of Sexual Medicine publications are reviewed in this article. Although evidence supports an integrated biopsychosocial approach to assessment and treatment of these disorders, the biological and psychological factors are artificially separated for review purposes. We recognize that best outcomes are achieved when all relevant factors are identified and addressed by the clinician and patient working together in concert (the sum is greater than the whole of its parts). Kingsberg SA, Althof S, Simon JA, et al. Female Sexual Dysfunction-Medical and Psychological Treatments, Committee 14. J Sex Med 2017;14:1463-1491.
Authors: Kathryn E Flynn; Dane Whicker; Li Lin; Rachel Cusatis; Alan Nyitray; Kevin P Weinfurt Journal: J Gen Intern Med Date: 2019-08-26 Impact factor: 5.128
Authors: Sheryl A Kingsberg; Jonathan Schaffir; Brooke M Faught; JoAnn V Pinkerton; Sharon J Parish; Cheryl B Iglesia; Jennifer Gudeman; Julie Krop; James A Simon Journal: J Womens Health (Larchmt) Date: 2019-02-04 Impact factor: 2.681
Authors: Imad Bentellis; Gérard Amarenco; Xavier Gamé; Dora Jericevic; Mehdi El-Akri; Caroline Voiry; Lucas Freton; Juliette Hascoet; Quentin Alimi; Jacques Kerdraon; Benjamin M Brucker; Benoit Peyronnet Journal: Clin Auton Res Date: 2019-08-26 Impact factor: 4.435
Authors: Sharon J Parish; James A Simon; Susan R Davis; Annamaria Giraldi; Irwin Goldstein; Sue W Goldstein; Noel N Kim; Sheryl A Kingsberg; Abraham Morgentaler; Rossella E Nappi; Kwangsung Park; Cynthia A Stuenkel; Abdulmaged M Traish; Linda Vignozzi Journal: J Womens Health (Larchmt) Date: 2021-04-01 Impact factor: 2.681
Authors: Susan R Davis; Rodney Baber; Nicholas Panay; Johannes Bitzer; Sonia Cerdas Perez; Rakibul M Islam; Andrew M Kaunitz; Sheryl A Kingsberg; Irene Lambrinoudaki; James Liu; Sharon J Parish; JoAnn Pinkerton; Janice Rymer; James A Simon; Linda Vignozzi; Margaret E Wierman Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958